A Phase 4 interventional study of Propranolol 80 mg and Flunarizine 10 mg in Migraine Prophylaxis, sponsored by Chittagong Medical College. Not yet recruiting at 1 site in Bangladesh. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-06-22.
Sponsored by Chittagong Medical College · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing propranolol in Migraine Disorders — 7 open to participants now, 7 under way, 2 of them phase 3. Propranolol · Migraine Disorders.
Among the 13 studies testing propranolol in Migraine Disorders, this one is the 7th largest by planned enrollment, is one of 2 that started in 2026, is one of 5 in phase 4, and was the 12th registered.
1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →7 of the 13 studies testing propranolol in Migraine Disorders are open now, in 4 countries. Recruiting first, the newest first:
Muhammad Aamir Latif · Sites in Pakistan
Ages 8–15
Mayo Clinic · Sites in United States
Ages 18–70
Kafrelsheikh University · Sites in Egypt
Ages 10–55
Kafrelsheikh University · Sites in Egypt
Ages 18–75
Sohag University · Sites in Egypt
Ages 18–60 · Healthy volunteers
By country, each count listing its studies:
Propranolol: first FDA approval 1967 (INDERAL), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 177 is above the median of 80 across 1,271 interventional studies indexed under Migraine Disorders.
Median enrollment 177 across the 13 interventional studies. Of the 4 that completed or were terminated, 1 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 13 have an industry lead sponsor. The 10 most frequent:
Chittagong Medical College is the lead sponsor of 15 studies on the registry; 8 are open to participants now.
Chittagong Medical College has 1 study filed under Migraine Disorders — fewer than ten, so there is no comparison to draw.
2 of the studies testing propranolol in Migraine Disorders that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07849283Sohag UniversityEfficacy of Cognitive Behavioral Therapy at Vestibular Migraine | 2027-02 |
| NCT07655700Chittagong Medical CollegeComparison of Propranolol, Flunarizine and Their Combination in Preventing Migraine in Adults in a Tertiary Care Hospital in Bangladesh | 2027-03-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies testing propranolol in Migraine Disorders, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Migraine is a common and disabling neurological condition that affects quality of life, work productivity, and daily functioning. In Bangladesh, migraine is a major health problem, yet access to effective and affordable preventive treatments remains limited. Preventive (prophylactic) treatment is recommended for people who experience frequent migraine attacks in order to reduce the number, severity, and duration of headaches.
Propranolol and flunarizine are two commonly used and relatively inexpensive medications for migraine prevention. Both drugs have been shown to reduce migraine frequency when used alone. However, some patients do not respond adequately to a single medication. Using a combination of drugs that work through different mechanisms may improve treatment effectiveness without significantly increasing side effects. There is limited local evidence comparing propranolol, flunarizine, and their combination in migraine prevention, particularly in the Bangladeshi population.
This study is designed to compare the effectiveness and safety of propranolol alone, flunarizine alone, and a combination of propranolol and flunarizine in preventing episodic migraine in adults. The main hypothesis is that at least one of these treatment strategies, particularly combination therapy, may be more effective than the others in reducing migraine burden.
This is an open-label, parallel-arm, randomized controlled trial conducted at Chittagong Medical College Hospital, Bangladesh. A total of 177 adult patients aged 18 to 55 years who are diagnosed with episodic migraine and experience four or more migraine attacks per month will be enrolled. Participants will be randomly assigned to one of three treatment groups: propranolol, flunarizine, or a combination of both medications. Treatment will be given for 12 weeks, with dose adjustments during the first week and follow-up visits at 6 and 12 weeks.
The primary outcome of the study is the reduction in the number of monthly migraine days. Secondary outcomes include the proportion of patients achieving at least a 50% reduction in migraine days, changes in headache severity and duration, improvement in migraine-related disability (measured by the Migraine Disability Assessment Score), patient-reported treatment satisfaction, and the frequency of side effects.
The results of this study are expected to provide important local evidence to guide clinicians in selecting effective and affordable migraine preventive treatments and to clarify whether combination therapy offers additional benefits over single-drug therapy in routine clinical practice.
Migraine is a highly prevalent neurological disorder, and in Bangladesh it accounts for approximately 25% of all headache disorders, predominantly affecting individuals aged 15-34 years and imposing a substantial socioeconomic burden through lost work hours and reduced productivity. Propranolol (a non-selective beta-blocker) and flunarizine (a calcium channel blocker) are both established first-line agents for migraine prophylaxis, but head-to-head comparative data in the Bangladeshi population are scarce, and evidence on their combined use remains limited. Prior trials comparing the two agents have produced mixed results, with some favoring flunarizine, others favoring propranolol, and others showing no significant difference. A subset of patients (30-40%) fail to respond adequately to monotherapy, and combination therapy targeting both beta-adrenergic and calcium-channel mechanisms has shown promise in earlier small trials without a clear increase in adverse events.
This study is an open-label, parallel-arm randomized controlled trial conducted in the inpatient and outpatient departments of Neurology and Medicine at Chittagong Medical College Hospital (CMCH), Chattogram, Bangladesh, over a planned duration of 18 months (12-week intervention period per participant, with follow-up at 6 and 12 weeks).
A total of 177 adult patients with episodic migraine (diagnosed per ICHD-3 criteria) will be enrolled using consecutive sampling and randomly allocated via software-generated block randomization (block size of six) with allocation concealment using sealed opaque envelopes, to one of three parallel groups (59 participants per group):
Group 1 (Propranolol): Started at 40 mg daily, increased to 80 mg daily after 7 days.
Group 2 (Flunarizine): Started at 5 mg daily, increased to 10 mg daily after 7 days.
Group 3 (Combination): Propranolol 40 mg plus flunarizine 5 mg daily initially; after 7 days, propranolol maintained at 40 mg while flunarizine is increased to 10 mg daily.
Acute attacks during the study may be managed with naproxen (NSAID) as first-line and zolmitriptan (triptan) if naproxen is ineffective.
At baseline, participants undergo a comprehensive evaluation including demographic data, general and systemic examination, baseline laboratory testing (ECG, RBS, SGPT, SGOT, serum creatinine), migraine history (frequency, duration, severity), MIDAS (Migraine Disability Assessment) score using a Bengali-translated version adopted with author permission, and headache severity (Numeric Rating Scale) and duration. Participants maintain a daily headache diary throughout the study.
Follow-up visits occur at 6 and 12 weeks, during which the headache diary is reviewed, adverse effects are recorded, treatment adherence is assessed by self-report and pill counting [(pills dispensed - pills returned) / pills expected to be taken × 100, with ≥80% considered adherent], MIDAS score is re-assessed at study end, headache severity/duration are reassessed, and Patient Global Evaluation (1-4 Likert scale) is recorded. Vital signs (pulse, blood pressure) and BMI are recorded at each visit. Participants experiencing intolerable adverse effects may be withdrawn and offered alternative treatment.
The primary outcome is the reduction in number of monthly migraine days from baseline to 12 weeks, analyzed using ANCOVA adjusting for baseline values and potential confounders (age, gender, baseline headache frequency), with Bonferroni-corrected pairwise comparisons between the three groups. Secondary analyses include repeated-measures ANOVA for headache severity (NRS), Wilcoxon signed-rank or paired t-tests for MIDAS score change, and Chi-square/Fisher's exact tests for responder rate (≥50% reduction in monthly migraine days at week 12) and adverse effect frequency. Exploratory subgroup analyses by age (\<40 vs ≥40 years) and gender will be conducted using ANCOVA or logistic regression as appropriate. Both intention-to-treat and per-protocol analyses will be performed, with missing data handled via ITT principles and multiple imputation if needed. Effect sizes (Cohen's d, partial eta squared) and 95% confidence intervals will be reported for all point estimates. Analyses will be performed using SPSS version 27.0 or later, with statistical significance set at p \< 0.05.
Informed consent will be obtained from all participants prior to enrollment. Detailed information about the study's objectives, procedures, potential risks, benefits, and the voluntary nature of participation will be provided in a written format. Participants will be given ample opportunity to ask questions and will be informed that they may withdraw from the study at any time without consequence.
Confidentiality will be maintained at all stages of the study. All participant data will be anonymized using a unique identifier, and personal identifying information will be stored securely. Data will be analyzed and reported in aggregate form to protect participant anonymity. Only authorized personnel will have access to the study data.
A Data Safety and Monitoring Committee (DSMC) will ensure participant safety and the ethical conduct of the trial. The DSMC will periodically review safety data, adverse events, serious adverse events, protocol deviations, dropout patterns, and overall trial progress. If any participant experiences intolerable side effects or other health concerns, appropriate medical intervention will be provided, and the participant will be withdrawn from the study if necessary. Any serious adverse events will be reported to the DSMC and ethics committee in accordance with ethical guidelines.
Finally, the ethical principle of beneficence will be upheld by ensuring that the potential benefits of participation outweigh any risks. The study will aim to improve the management of migraines, leading to better patient outcomes and a more efficient healthcare system, particularly in underserved regions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Comorbidities:
Medications:
Non-compliance:
History of Allergies:
Substance Use:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to this arm will receive propranolol as the sole prophylactic medication for migraine, administered for a total of 12 weeks. Propranolol will be started at 40 mg daily and increased to 80 mg daily after 7 days
Drug: Propranolol 80 mg
Participants randomized to this arm will receive flunarizine as the sole prophylactic medication for migraine, administered for a total of 12 weeks. Flunarizine will be started at 5 mg daily and increased to 10 mg daily after 7 days
Drug: Flunarizine 10 mg
Participants randomized to this arm will receive a combination of propranolol and flunarizine for migraine prophylaxis, administered for a total of 12 weeks. Treatment will be started at propranolol 40 mg daily plus flunarizine 5 mg daily. After 7 days, the propranolol dose will be maintained at 40 mg daily while the flunarizine dose will be increased to 10 mg daily.
Drug: Propranolol 40 mg + Flunarizine 10mg
Participants randomized to propranolol arm will receive propranolol as the sole prophylactic medication for migraine, administered for a total of 12 weeks. Propranolol will be started at 40 mg daily and increased to 80 mg daily after 7 days
Participants randomized to flunarizine arm will receive flunarizine as the sole prophylactic medication for migraine, administered for a total of 12 weeks. Flunarizine will be started at 5 mg daily and increased to 10 mg daily after 7 days
Drug page: PropranololStudies of PropranololPropranolol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Participants randomized to combination arm will receive a combination of propranolol and flunarizine for migraine prophylaxis, administered for a total of 12 weeks. Treatment will be started at propranolol 40 mg daily plus flunarizine 5 mg daily. After 7 days, the propranolol dose will be maintained at 40 mg daily while the flunarizine dose will be increased to 10 mg daily.
Change in Monthly Migraine Days
Monthly Migraine Days refers to the total number of days within a month on which a participant experiences a migraine headache. The change will be measured as the difference between the baseline number of monthly migraine days and the number recorded at the end of the study.
Time frame: From baseline to 12 weeks
Responder Rate (≥50% reduction in monthly migraine days)
The percentage of patients reporting at least a 50% reduction in their monthly migraine days compared to the baseline. This will be expressed as the percentage of total participants in each treatment arm.
Time frame: Baseline to 12 weeks
Change in Headache Severity (Numeric Rating Scale)
Intensity of migraine pain rated by participants on a Numeric Rating Scale from 0 (no pain) to 10 (worst pain imaginable), recorded in the headache diary and reviewed at follow-up visits.
Time frame: Baseline, Week 6, and Week 12
Change in Headache Duration
Length of time (in hours) of each migraine attack, from onset of pain to resolution, as recorded by participants in the headache diary and reviewed at follow-up visits.
Time frame: Baseline, Week 6, and Week 12
Change in MIDAS (Migraine Disability Assessment) Score
Score from the Bengali-translated MIDAS questionnaire (adapted from Alam et al., 2018, used with author's permission), measuring migraine-related disability across work/school, household duties, and other daily activities, graded from Grade 1 (minimal disability) to Grade 4 (severe disability).
Time frame: Baseline and end of treatment (Week 12)
Patient Global Evaluation
Participant's self-reported overall impression of treatment effectiveness, rated on a 4-point Likert scale (1 = Poor, 2 = Good, 3 = Very good, 4 = Excellent).
Time frame: End of the treatment Week 12
Frequency of Adverse Effects
Number and proportion of participants in each treatment group reporting any adverse effect (harmful or unpleasant effect at therapeutic doses requiring dose reduction or drug withdrawal) during the treatment period, recorded at follow-up visits.
Time frame: Throughout the 12-week treatment period (assessed at Week 6 and Week 12)
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Start is estimated for Jul 2026; primary completion for Mar 2027, 8 months later.
Of 49 non-industry phase 4 interventional studies under Migraine Disorders, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 51. This study's planned 8 months is below that.
Counting every sponsor, half of 77 studies reached it within 27 months; a quarter within 17 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Propranolol · Flunarizine
Chittagong Medical College